May 09
I am thrilled to share that our invited Feature Review — led by graduate researcher Aurelie Brownsberger as lead author with significant contributions from undergraduate researchers in our group— is now published in MDPI’s Journal of Nanotheranostics (JNT), as part of the Special Issue: Feature Review Papers in Nanotheranostics. Title: Intrinsically Selective Nanoplatforms for Precision …
Apr 20
A few weeks ago, I shared the news of Kendall Bradley’s outstanding performance at the Northern Indiana Regional Science and Engineering Fair (NIRSEF). I am thrilled to follow up with another reason to celebrate. At the Hoosier Science and Engineering Fair / Indiana State Science Fair, Kendall earned the 2nd Place Award from the American …
Mar 28
The Society For Biomaterials (SFB) 2026 Annual Meeting & Exposition brought our lab to the Hyatt Regency Atlanta from March 25–28, 2026, and it was one of the most rewarding conferences for us this year. The lab had three contributions spanning our antibiofilm-coating, antimicrobial drug-delivery, and cancer-theranostic programs, and I was particularly honored to be …
Mar 23
I am thrilled to share that Aurelie Brownsberger, a graduate researcher working on a PD[N]ano Lab project, was selected for an oral presentation at the 14th Annual Harper Cancer Research Day, held on Monday, March 23, 2026 at the University of Notre Dame. This is a meaningful distinction. Of the more than 100 abstracts submitted …
Mar 17
I am delighted to share that on March 17, 2026, the United States Patent and Trademark Office officially issued U.S. Patent No. 12,576,160 for our technology, “Bispecific bridge nanoparticles for efficient targeting of cancer cells using immunotherapy (universal CAR-T cells) or chemotherapeutic” (Notre Dame docket P21-043-US01). This is the same invention that received its Notice …
Feb 12
I had a fantastic time visiting Rosalind Franklin University of Medicine and Science to speak at the Innovation Sciences Seminar Series hosted by the Center for Proteomics and Molecular Therapeutics (PMT) on February 12, 2026. It was a privilege to share my team’s work on “Label-Free Targeting of Therapeutics to Cancer Cells or Multi-Drug Resistant …
NIH Funding Opportunities
Recent Comments